Companies › Axogen
1 active drug program in 1 registered trial: 1 Phase 4; Other; next expected readout Dec 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Avance Nerve Graft Acellular nerve allograft scaffold derived from decellularized and sterilized extracellula | – | Phase 4 | Peripheral Nerve Injury | Dec 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07657182 | Avance Nerve Graft | Phase 4 | Peripheral Nerve Injury | Other | Dec 2030 |
Cash and short-term investments of $348m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
No annotated target.
–
CellTherX CUTISS Gameto Merz Aesthetics DBV Technologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.